The Quantellect read.As of Nov 19, 2026, 3 active firms cover Precision BioSciences Inc: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $20.00 to $60.00 (about 3.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $36.67 sits 417% above the current $7.09. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.42 next quarter toward $-2.19 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$36.67
+416.8% upside
Average target across 3 active firms as of Nov 19, 2026 vs $7.10 current
Highest Target$60.00
Average Target$36.67
Lowest Target$20.00
Detailed analyst forecasts for DTIL
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate DTIL a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
DTIL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.42
Range $-0.42 – $-0.42 · 1 analysts · -44% YoY
Next period, 1 analysts expect Precision BioSciences Inc to earn $-0.42 a share (range $-0.42 – $-0.42), versus $-0.75 a year earlier. Full-year consensus is $-2.85, growing to $-2.19 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts · -100% YoY
Revenue is expected to reach $0 (range $0 – $0), -100.0% year-over-year. Full-year consensus is $11.3M, rising to $8.7M next year.
Top analysts covering Precision BioSciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DTIL.
#1
Debjit Chattopadhyay
Guggenheim · Rank #248
Buy
$19.00+167.8% to target
Overall win rate
39%
+ Follow
#2
Patrick R. Trucchio
HC Wainwright & Co. · Rank #308
Buy
$60.00+745.7% to target
Overall win rate
36%
+ Follow
#3
CN
Catherine Novack
JonesTrading
Buy
$30.00+322.8% to target
Coverage
—
+ Follow
#4
KB
Kostas Biliouris
Oppenheimer
Buy
$20.00+181.9% to target
Coverage
—
+ Follow
#5
Catherine Novack
Jones Trading
Buy
$30.00+322.8% to target
Coverage
—
+ Follow
DTIL stock forecast FAQ
What is DTIL's average 12-month price target?+
The 3 active firms with a live target average $36.67 for Precision BioSciences Inc over the next 12 months, ranging from a $60.00 high to a $20.00 low, as of Nov 19, 2026.
Is DTIL stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for DTIL?+
The Street-high target is $60.00 (HC Wainwright & Co.), and the Street-low is $20.00 (Oppenheimer). The average of all 3 active-firm targets is $36.67.
How many active Wall Street firms cover DTIL?+
3 active firms have a recognized rating on Precision BioSciences Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering DTIL?+
Among analysts who currently cover DTIL, Debjit Chattopadhyay of Guggenheim has the strongest overall Quantellect track record (Rank #248). Their current call is Buy with a $19.00 target.
What is Precision BioSciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.42 per share (range $-0.42 – $-0.42) across 1 analysts. Full-year EPS is projected at $-2.85, rising to $-2.19 the following year.
How much revenue is Precision BioSciences Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $11.3M, growing to $8.7M next year.
Have analysts been upgrading or downgrading DTIL lately?+
As of Nov 19, 2026, 3 of 3 active firms rate DTIL a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DTIL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.